Healthcare
Abbott Laboratories(ABT)
Data coverage status · 6 need attention
Quote through 2026-08-05T13:30:00Z · Stale
Quote synced 2026-08-05T22:30:33.814839Z
Daily bars through 2026-08-03 · Stale
Daily bars synced 2026-08-04T15:35:19.331132Z
Fundamentals through 2026-05-04 · Current
Fundamentals synced 2026-08-05T21:09:44.603401Z
Forecasts: Stale
Forecasts synced 2026-05-05T11:57:48.711655Z
Ownership: Missing
Ownership synced 2026-08-05T21:09:44.603401Z
Short interest: Missing
Short interest synced 2026-08-05T21:09:44.603401Z
News through 2026-05-21T02:30:00Z · Stale
News synced 2026-05-21T08:13:40.628796Z
Company profile: Delayed
Company profile synced 2026-05-06T21:57:49.68488Z
Regular-session price
Offline$105.71
+0.24% regular session
1Y Change
-19.06%
Window
Aug 5, 2025 → Aug 4, 2026
- Market Cap
- $152.55B
- P/E
- 24.4
- Trailing
- 52W Range
- $81.97 - $137.49
- Volume
- 8.73M
- 0.4x RVOL
Investment Snapshot
Valuation, growth, profitability, catalysts, and benchmark context.
1D
+0.2%
1M
+10.6%
6M
-2.2%
YTD
-14.8%
1Y
-19.1%
- Market Cap
- $152.55B
- NYSE
- P/E
- 24.4
- Trailing valuation
- Revenue Growth
- +5.7%
- TTM growth
- EPS Growth
- -51.2%
- TTM earnings growth
- Operating Margin
- 18.2%
- TTM profitability
- Forward P/E
- —
- Waiting on consensus EPS
- Next Earnings
- Oct 16, 2026
- In 72 days
- 52W Position
- 43%
- $81.97 - $137.49
- Volume
- 0.4x
- 8.73M shares latest
- Benchmark
- -41.89 pts
- vs SPY over 1Y
- Dividend
- 2.8%
- Last ex-date Apr 15, 2026
Coverage: 250 bars · Aug 5, 2025 → Aug 4, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Abbott Laboratories (ABT) is a Healthcare stock with listed on NYSE. The stock last traded around $105.71 and down 19.1% across the available one-year price window (Aug 5, 2025 → Aug 4, 2026). Baseline metrics include revenue growth of +5.7%, EPS growth of -51.2%, a dividend yield of 2.8%. What stands out right now is revenue +5.7%, EPS -51.2%, free cash flow +16.4% with operating margin 18.2% and ROIC 6.6%. The dividend matters to the case here, with a current yield around 2.8%. Valuation is more restrained than many high-expectation growth names at P/E 24.4 and price/sales 3.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ABT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+5.7% vs +7.6% peer median
Operating Margin
Above sector median
+18.2% vs +11.7% peer median
P/E
Below sector median
24.4 vs 101.5 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
Q2 2026 was reported on Apr 16, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +5.7% and EPS is at -51.2%, with operating margin around 18.2%.
The next real check-in already has a date
The next earnings event is scheduled for Oct 16, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.2% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Delta | 1D | 5D | 20D |
|---|---|---|---|---|
Q2 2026 Apr 16, 2026 | +0.0% | +1.4% | -3.1% | -11.1% |
Q1 2026 Jan 22, 2026 | +0.7% | -1.1% | -2.3% | +3.3% |
Q4 2025 Oct 15, 2025 | +0.0% | -1.4% | -1.2% | -0.5% |
Benchmark Edge
ABT vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
ABT trails SPY
ABT is 41.89 pts behind over the shared 1Y window.
ABT had 30.44 pts deeper max drawdown than SPY.
ABT beat SPY in 0 of 2 calendar years shown and trailed in 2.
ABT
-19.06%
Normalized return
SPY
+22.83%
S&P 500
Excess Return
-41.89 pts
Relative to SPY
ABT Max Drawdown
-39.57%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ABT and SPY.
| Year | ABT | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | -14.82% | +12.67% | -27.50 pts | SPY |
| 2025 | -3.76% | +9.40% | -13.16 pts | SPY |
Company Overview
Abbott Laboratories
New York Stock Exchange
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
- Leadership
- Robert Ford
- IPO Date
- Mar 17, 1980
- Employees
- 114.0k
- Street Address
- 100 Abbott Park Road
- Mailing
- Abbott Park, IL, 60064-6400
- Region
- Abbott Park, IL, US
- Reporting Currency
- USD
- Investor Line
- 224 667 6100
- Last Updated
- May 6, 2026
Statistics & Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 24.4
- EV/EBITDA
- 16.6
- Price/Sales
- 3.4
- Price/Book
- 2.9
Growth
- Revenue
- +5.7%
- EPS
- -51.2%
- Free Cash Flow
- +16.4%
Profitability
- Gross Margin
- 56.4%
- Operating Margin
- 18.2%
- Net Margin
- 13.9%
- ROE
- 12.2%
- ROIC
- 6.6%
Balance Sheet
- Debt/Equity
- 0.65
- Current Ratio
- 1.39
Earnings Reports
Latest News
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.